小鼠CD1d1编码区基因的克隆与鉴定

目的:克隆小鼠CD1d1编码区基因。方法:提取小鼠小肠组织总RNA,用RT-PCR技术扩增小鼠CD1d1编码基因,PCR产物连接pGEM-T载体,转化大肠杆菌,用限制性酶切和DNA序列测定对阳性克隆进行鉴定。结果:扩增出一条与预期片段大小相符的特异DNA条带,限制性酶切应显示目的基因片段插入T载体,序列测定表明所获取的基因大小为1011bp。结论:成功克隆了小鼠CD1d1编码基因,为进一步重组蛋白及其抗体的制备奠定了基础。     

大鼠FasL基因克隆及重组慢病毒载体pLO134-FasL的构建

目的 克隆大鼠FasL基因全长序列,构建其用于真核细胞表达的重组慢病毒载体pLO134-FasL,为进一步研究FasL蛋白生物学功能奠定基础.方法 根据大鼠FasL cDNA序列设计合成上、下游引物,以大鼠脾细胞提取的总RNA为模板,行RT-PCR扩增.扩增片断经限制性内切酶BamHⅠ和EcoRⅠ双酶切后,插入慢病毒载体pLO134中并转化感受态细胞JM101.扩增后酶切鉴定,对正确的阳性克隆行DNA全序列分析.结果 RT-PCR扩增获得870 bp DNA片段,DNA序列分析结果与发表于GenBank上的序列（U03470）完全一致.结论 成功克隆大鼠FasL基因并构建其用于真核细胞表达的重组慢病毒载体pLO134-FasL.     

一个新的C2H2型锌指蛋白cDNA基因的克隆

目的：从K562细胞中克隆新的锌指蛋白cDNA基因片段。方法：提取K562细胞中总RNA,逆转录后,用CX2C和H－C Link引物进行加端PCR,扩增产物经限制性内切酶酶切后,重组至pGEMTZf( )载体,用末端终止法测定插入片段的序列。结果：测出五个插入片段的序列。与GenBank核酸数据库中的已知序列进行同源性比较分析,发现一个序列为新的cDNA基因片段。该基因编码产物至少含有五个C2H2型锌指结构。结论：从K562细胞中克隆出一个新的C2H2型锌指蛋白cDNA基因片段,为测定该基因的全序列和功能研究奠定了基础。     

推定编码嗜麦芽黄单胞菌整合酶类蛋白基因片段的克隆

目的扩增编码嗜麦芽黄单胞菌CG类受体的核酸序列。方法根据Grover报道的嗜麦芽黄单胞菌CG类受体的342 bp部分核酸序列设计的一特异引物P1和随机引物进行PCR扩增，将PCR产物克隆到pUCm-T载体上，对经酶切鉴定筛选的重组质粒上的插入片段进行测序和分析。结果将约500 bp PCR产物克隆到pUCm-T载体上，经酶切鉴定筛选得到重组质粒pUCm-Int。pUCm-Int上插入片段经M13通用引物测序，510 bp克隆片段(GenBank注册号为：AY363962)的410～486 bp与柑橘黄单胞菌质粒pXAC64上的XACb0009基因的9034～8958 bp部分有84％同源序列，由510 bp核酸序列编码的169氨基酸(aa)序列的4～166aa部分与柑橘黄单胞菌XACb0009基因编码的424aa整合酶类蛋白的38～200aa序列有62％同源序列。结论克隆到的510 bp核酸序列可能是编码嗜麦芽黄单胞菌整合酶类蛋白的部分基因序列。     

人CCR5Delta32基因的克隆及其重组慢病毒载体的构建

目的:克隆人CCR5Delta32基因并构建含目的基因的重组慢病毒载体pLenti-CCR5Delta32,用于获得性免疫缺陷综合征(AIDS)的基因治疗研究. 方法:从CCR5Delta32突变个体外周血单个核细胞(PBMCs)内提取人基因组DNA,利用PCR技术扩增CCR5Delta32全长基因,经EcoRI单酶切后与pUCm-T载体连接,随后转化感受态E.coli DH5α,提取质粒进行酶切鉴定及DNA测序. 再将鉴定正确的CCR5Delta32基因亚克隆至慢病毒载体pLenti6/V5-D-TOPO并进行酶切鉴定及DNA序列分析. 结果:经PCR扩增获得约650 bp的DNA片段,测序结果与GenBank上的序列完全一致,克隆的目的基因已经正确插入到慢病毒载体pLenti6/V5-D-TOPO中. 结论:成功克隆了人CCR5Delta32基因并构建了含目的基因的重组慢病毒载体pLenti-CCR5Delta32,为进一步AIDS基因治疗研究奠定基础.     

人Gfil基因克隆及重组Gfil慢病毒表达载体的构建

目的 克隆人Gill基因的全长cDNA,构建用于真核细胞表达的含有Gfil基因ORF区的重组慢病毒表达载体pLOX-Gfil,为研究Gfil基因的功能打下基础.方法 应用RT-PCR从人K562细胞系中扩增出Gfil cDNA片段·经回收纯化与pGEM-T载体连接并转化感受态菌DH5a,通过蓝白筛选酶切鉴定出阳性菌落,质粒提取,BamH I限制性内切酶酶切获得目的 基因,插入慢病毒载体pLOX中并转化感受态细菌DH5a.质粒提取后进行酶切及PCR鉴定,对阳性克隆进行DNA序列分析.结果 RT-PCR扩增获得含有约1.2 kb的DNA片段,酶切及PCR鉴定证实pLOX-Gfil含有大小正确的正向Gfil cDNA,DNA序列分析的结果 与发表于GenBank上的序列(NM005263)完全一致.结论 成功克隆人Gfil基因并构建用于真核细胞表达的重组慢病毒载体pLOX-Gfil.     

SARS病毒M蛋白编码基因在大肠杆菌中的克隆与表达

目的：克隆SARS冠状病毒膜蛋白M胞外区编码序列，并将其置于大肠杆菌作融合表达。方法：从GenBank获得SARS病毒BJ01株膜蛋白M编码基因序列，人工合成其氨基端129-base-pair(bp)双向单链DNA序列，在5’和3’端分别引入BamHⅠ、Ⅰ酶切位点，退火后形成双链DNA，常规法将其克隆到原核表达载体pGEX-6p-1中，构建含M蛋白编码基因的重组原核表达质粒。重组质粒经酶切鉴定，核酸序列测定和分析后转化大肠杆菌(E．co如)BL21感受态细胞，以异丙基硫代一B—D一半乳糖苷(IPTG)诱导表达融合蛋白。结果：核酸序列测定与分析的结果表明，克隆的129bp基因序列与基因数据库中所登记的BJ01毒株序列呈现100％同源性。IPTG诱导后的菌体，经SDs-聚丙烯酰胺凝胶电泳(PAGE)，显示有一个大小为30．1ku的融合表达蛋白产生。结论：M蛋白氨基端胞外区129bp编码基因在E.coli中获得正确表达。     

人幽门螺杆菌热休克蛋白A编码基因的克隆及表达

目的:扩增人幽门螺杆菌(Helicobacter py lori,Hp)热休克蛋白A(heat shock prot ein A,HspA)编码基因并构建其重组表达载体,进行核苷酸序列分析,并在E.coli BL21中表达,为疫苗的开发奠定了基础.方法:利用PCR技术从Hp基因组DNA中扩增热休克蛋白A(HspA)基因片段,目的基因经SacⅠ和XhoⅠ双酶切、纯化后,插入pET32a(+)载体.以含目的基因片段的重组载体转化大肠杆菌BL21并表达.结果:经PCR、酶切、测序分析表明 ,插入的基因片段为Hp HspA编码基因,与GenBank报道的相比较,核酸同源性达98%.经SDS-PAGE 分析,表达的融合蛋白分子量约为33 KD,其中目的蛋白的分子量约为13 KD.结论:成功地克隆并表达了Hp HspA编码基因,为HspA蛋白质疫苗的研制和快速诊断试剂盒的开发奠定了良好的基础.     

SPRR1A基因真核荧光表达载体的构建

目的:构建可在真核细胞中表达SPRR1A(small proline-rich repeat protein1A)的荧光表达载体。方法:应用PCR技术扩增出编码SPRR1A的全长基因,将SPRR1A DNA克隆到pEGFP-N1质粒,通过抗性基因筛选阳性克隆,经酶切和测序鉴定。结果:酶切和DNA序列鉴定均证实插入片段与GenBank提供的序列(L05187)一致。结论:成功构建了SPRR1A真核荧光表达载体。     

羊布鲁氏菌omp25基因原核表达载体的构建与鉴定

目的:利用PCR反应从羊布鲁氏菌基因组DNA中克隆omp25基因,并将其构建到原核表达载体pET-32a中。方法:试剂盒法提取羊布鲁氏菌基因组DNA,设计合适的引物,通过PCR反应从基因组中扩增外膜蛋白OMP25的编码基因(omp25)。将得到的基因片段连接到克隆载体pMD19-T的多克隆位点(MCS)中,将连接体pMD19-T-omp25转化感受态大肠杆菌DH5(并进行筛选和克隆扩增,提取质粒并进行酶切分析与序列测定。利用酶切与连接反应将目的基因(omp25)插入载体pET-32a的多克隆位点中,将连接体pET-32a-omp25转化感受态大肠杆菌DH5(并进行筛选和克隆扩增,提取质粒并进行酶切分析。结果:PCR扩增得到的基因片段与GenBank中已公布的羊布鲁氏菌omp25基因同源性为99%。酶切分析结果表明,omp25基因成功地插入载体pET-32a中。结论:成功地扩增得到了羊布鲁氏菌omp25基因并构建了携带该基因的重组原核表达载体pET-32a-omp25,为后续的研究提供了可靠的基础。     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…